IS6986A - Lyfjasamsetning í vökvaformi - Google Patents

Lyfjasamsetning í vökvaformi

Info

Publication number
IS6986A
IS6986A IS6986A IS6986A IS6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
IS6986A
Other languages
English (en)
Other versions
IS2428B (is
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS6986A publication Critical patent/IS6986A/is
Publication of IS2428B publication Critical patent/IS2428B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
IS6986A 2001-05-25 2003-10-09 Fljótandi lyfjasamsetning IS2428B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (2)

Publication Number Publication Date
IS6986A true IS6986A (is) 2003-10-09
IS2428B IS2428B (is) 2008-10-15

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6986A IS2428B (is) 2001-05-25 2003-10-09 Fljótandi lyfjasamsetning

Country Status (43)

Country Link
US (2) US20020198261A1 (is)
EP (1) EP1395242B1 (is)
JP (1) JP2004534764A (is)
KR (1) KR100582963B1 (is)
CN (1) CN100346779C (is)
AP (1) AP1815A (is)
AR (1) AR033922A1 (is)
AT (1) ATE334656T1 (is)
AU (1) AU2002258026B2 (is)
BG (1) BG108376A (is)
BR (1) BR0209973A (is)
CA (1) CA2446574C (is)
CR (1) CR7150A (is)
CY (1) CY1105147T1 (is)
CZ (1) CZ299755B6 (is)
DE (1) DE60213592T2 (is)
DK (1) DK1395242T3 (is)
DO (1) DOP2002000403A (is)
EA (1) EA008087B1 (is)
EE (1) EE200300587A (is)
EG (1) EG24078A (is)
ES (1) ES2265040T3 (is)
GE (1) GEP20053620B (is)
HR (1) HRP20030833B1 (is)
HU (1) HUP0401366A2 (is)
IL (1) IL158359A0 (is)
IS (1) IS2428B (is)
MA (1) MA27026A1 (is)
MX (1) MXPA03009392A (is)
MY (1) MY128615A (is)
NO (1) NO20035200L (is)
NZ (1) NZ529173A (is)
OA (1) OA12604A (is)
PA (1) PA8545901A1 (is)
PE (1) PE20030087A1 (is)
PL (1) PL366384A1 (is)
PT (1) PT1395242E (is)
RS (1) RS87203A (is)
SI (1) SI1395242T1 (is)
SK (1) SK286227B6 (is)
SV (1) SV2003001053A (is)
WO (1) WO2002094220A1 (is)
ZA (1) ZA200308393B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2494811A1 (en) * 2002-08-15 2004-02-26 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
MXPA06003725A (es) * 2003-10-08 2006-06-23 Mallinckrodt Inc Solucion de fenidato de metilo y metodos asociados de administracion y produccion.
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
CN101039664A (zh) * 2004-10-14 2007-09-19 大金工业株式会社 气氛改变方法、用于该气氛改变方法的喷雾剂与喷雾装置
EP1915353A2 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Isophthalsäurediamide zur behandlung der alzheimer erkrankung
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) * 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US20210308044A1 (en) 2018-08-18 2021-10-07 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CN113631150A (zh) 2019-03-26 2021-11-09 奥赖恩公司 普瑞巴林制剂及其用途
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
MX2023008648A (es) 2021-01-22 2023-10-06 Egyt Gyogyszervegyeszeti Gyar Formulacion topica que contiene compuestos fosfolipidicos modificados.
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
CN118139617A (zh) * 2021-08-31 2024-06-04 艾维恩制药有限公司 稳定的加巴喷丁粉体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
CN1303991C (zh) * 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
WO2002043762A2 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
HUP0401366A2 (hu) 2004-11-29
CA2446574A1 (en) 2002-11-28
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
SI1395242T1 (en) 2006-10-31
NO20035200D0 (no) 2003-11-24
EP1395242A1 (en) 2004-03-10
EA008087B1 (ru) 2007-02-27
JP2004534764A (ja) 2004-11-18
BR0209973A (pt) 2004-04-06
SK14112003A3 (sk) 2004-08-03
RS87203A (sr) 2006-10-27
NZ529173A (en) 2005-07-29
CY1105147T1 (el) 2010-03-03
IS2428B (is) 2008-10-15
SV2003001053A (es) 2003-03-18
CZ299755B6 (cs) 2008-11-12
US7256216B2 (en) 2007-08-14
NO20035200L (no) 2003-11-24
EE200300587A (et) 2004-02-16
BG108376A (bg) 2005-04-30
HK1062646A1 (zh) 2004-11-19
SK286227B6 (sk) 2008-05-06
US20020198261A1 (en) 2002-12-26
DE60213592T2 (de) 2007-08-09
AU2002258026B2 (en) 2007-08-02
PE20030087A1 (es) 2003-02-14
EP1395242B1 (en) 2006-08-02
KR100582963B1 (ko) 2006-05-24
DK1395242T3 (da) 2006-10-30
WO2002094220A1 (en) 2002-11-28
KR20040003006A (ko) 2004-01-07
MA27026A1 (fr) 2004-12-20
PA8545901A1 (es) 2003-09-05
IL158359A0 (en) 2004-05-12
AR033922A1 (es) 2004-01-07
OA12604A (en) 2006-06-08
CN100346779C (zh) 2007-11-07
AP1815A (en) 2008-01-04
ATE334656T1 (de) 2006-08-15
US20040072904A1 (en) 2004-04-15
CA2446574C (en) 2008-04-01
HRP20030833B1 (en) 2007-04-30
CN1509165A (zh) 2004-06-30
HRP20030833A2 (en) 2004-08-31
GEP20053620B (en) 2005-09-26
EA200301152A1 (ru) 2004-04-29
ES2265040T3 (es) 2007-02-01
AP2003002907A0 (en) 2003-12-31
CZ20033066A3 (cs) 2004-08-18
EG24078A (en) 2008-05-11
DOP2002000403A (es) 2002-11-30
MY128615A (en) 2007-02-28
PL366384A1 (en) 2005-01-24
CR7150A (es) 2004-02-23
ZA200308393B (en) 2005-04-26
DE60213592D1 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
IS6986A (is) Lyfjasamsetning í vökvaformi
FI20011478L (fi) Farmaseuttinen koostumus
NO20033384D0 (no) Farmasöytisk formulering
NO20025450L (no) Ny farmasöytisk sammensetning
DK1524266T3 (da) Farmaceutisk sammensætning
NO20033785L (no) Farmasöytisk formulering
EE05020B1 (et) Glburiidi ravimkoostis
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
FI20022128A0 (fi) Farmaseuttinen koostumus
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20033073D0 (no) Farmasöytisk sammensetning inneholdende citalopram
NO20015534D0 (no) Farmasöytisk blandeapparat
FI20010970L (fi) Nestekoostumus
DE10107261B4 (de) Pharmazeutische Zusammensetzung
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
EP1413314A4 (en) MEDICAL COMPOSITIONS
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
NO20041236L (no) Farmasoytisk formulering